Last reviewed 2026-04-23 · How we verify

Lansoprazole, Bismuth Subsalicylate, Metronidazole, Tetracycline

Lansoprazole, Bismuth Subsalicylate, Metronidazole, Tetracycline is a Antibiotic combination therapy / H. pylori eradication regimen Small molecule drug developed by Soroka University Medical Center. It is currently in Phase 3 development for Helicobacter pylori infection eradication, Peptic ulcer disease associated with H. pylori.

This quadruple therapy combination eradicates Helicobacter pylori by reducing gastric acid, disrupting bacterial cell membranes, and inhibiting bacterial protein synthesis and DNA replication.

This quadruple therapy combination eradicates Helicobacter pylori by reducing gastric acid, disrupting bacterial cell membranes, and inhibiting bacterial protein synthesis and DNA replication. Used for Helicobacter pylori infection eradication, Peptic ulcer disease associated with H. pylori.

At a glance

Mechanism of action

Lansoprazole is a proton pump inhibitor that suppresses gastric acid secretion, creating an inhospitable environment for H. pylori. Bismuth subsalicylate provides direct antimicrobial activity against the bacteria. Metronidazole and tetracycline are antibiotics that target bacterial DNA replication and protein synthesis, respectively, working synergistically to eliminate the infection.

Approved indications

• Helicobacter pylori infection eradication
• Peptic ulcer disease associated with H. pylori

Common side effects

• Nausea
• Diarrhea
• Abdominal pain
• Metallic taste (metronidazole)
• Photosensitivity (tetracycline)
• Headache
• Black stool (bismuth)

Key clinical trials

• Prevalence of Asymptomatic H Pylori Infection Among Patients Undergoing PCI and Impact of Its Eradication on Occurrence of GIT Symptoms and Bleeding" (PHASE3)
• Sequential Therapy Versus Quadruple Therapy as Second Line Treatment After Failure of the Standard Triple Therapy for H Pylori Infection (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Lansoprazole, Bismuth Subsalicylate, Metronidazole, Tetracycline CI brief — competitive landscape report
• Lansoprazole, Bismuth Subsalicylate, Metronidazole, Tetracycline updates RSS · CI watch RSS
• Soroka University Medical Center portfolio CI

Frequently asked questions about Lansoprazole, Bismuth Subsalicylate, Metronidazole, Tetracycline

Related

• Drug class: All Antibiotic combination therapy / H. pylori eradication regimen drugs
• Target: All drugs targeting H. pylori (multiple targets: bacterial cell membrane, DNA, protein synthesis machinery)
• Manufacturer: Soroka University Medical Center — full pipeline
• Therapeutic area: All drugs in Gastroenterology / Infectious Disease
• Indication: Drugs for Helicobacter pylori infection eradication
• Indication: Drugs for Peptic ulcer disease associated with H. pylori
• Compare: Lansoprazole, Bismuth Subsalicylate, Metronidazole, Tetracycline vs similar drugs
• Pricing: Lansoprazole, Bismuth Subsalicylate, Metronidazole, Tetracycline cost, discount & access